publication venue for

• CAR-T cells co-targeting BCMA and CD19 in RRMM: Results from the UKMRA Phase 1 MCARTY trial in relapsed refractory multiple myeloma 2025
• Double hit ultra-high risk myeloma treated with isatuximab, bortezomib, lenalidomide, dexamethasone and cyclophosphamide (Isa-VRDc) induction and isa-VRD consolidation: Initial results of the UK myeloma research alliance (UKMRA) RADAR trial in newly diagnosed transplant eligible patients 2025
• Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial 2025
• A Novel Segmentation-Based Purity-Informed Approach Accurately Detects Total Copy Number and Its Subclonal Fraction in Myeloma Targeted Panel Sequencing Data 2024
• Evaluating Barriers to Enrolment into Multiple Myeloma (MM) Clinical Trials: Results from Health Care Professionals and Patient Survey from the UK Myeloma Research Alliance Equity, Diversity and Inclusivity (EDI) Working Group 2024
• Risk Assignment Using the Myeloma Genome Project Panel: A Comparison to Standard of Care Genetic Testing within the UK-MRA RADAR Trial 2024
• Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution 2024
• Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients 2023
• Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development 2023
• Targeted NGS Panel Guides Risk-Adapted Treatment Intention in Newly Diagnosed Myeloma Patients 2023
• The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma 2023
• Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures 2023
• Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens 2022
• Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy 2022
• Impact of Rare Structural Variant Events in Newly Diagnosed Multiple Myeloma 2022
• Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma 2022
• Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma 2022
• The Mutagenic Impact of Radiotherapy in Multiple Myeloma 2022
• Tracking the Earliest Genomic Events in Multiple Myeloma Life-History 2022
• Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures 2022
• Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin 2022
• Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms 2021
• Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes 2021
• Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd) 2021
• Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpassstudy 2021
• Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers 2021
• Unifying the Definition of High-Risk in Multiple Myeloma 2021
• A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis 2020
• Impact of Etiological Cytogenetic Abnormalities on Immunoparesis and Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma 2020
• Influence of Aging Processes on the Biology and Outcome of Multiple Myeloma 2020
• Treatment with Temozolomide and Ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL) 2020
• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Myeloma 2019
• Chromoplexy and Chromothripsis Are Important Prognostically in Myeloma and Deregulate Gene Function By a Range of Mechanisms 2019
• The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma 2019
• The Spectrum of Exomic Mutation in Elderly Myeloma Differs Substantially from Patients at Younger Ages Consistent with a Different Evolutionary Trajectory to Full Blown Disease Based on Age of Onset 2019
• Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03) 2019
• Efficacy and Safety of Daratumumab in a Frail Real-Life Relapsed or Refractory Systemic Light-Chain Amyloidosis Population (AL): Report on 15 Cases from the North of France 2018
• Extracting Prognostic Molecular Information from PF:T-CT Imaging of Multiple Myeloma Using Radiomic Approaches 2018
• Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma 2018
• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 2018
• Mutations and Copy Number Changes Predict Progression from Smoldering Myeloma to Symptomatic Myeloma in the Era of Novel IMWG Criteria 2018
• The Mutational Landscape of Primary Plasma Cell Leukemia 2018
• The genomic landscape of plasma cells in systemic light chain amyloidosis 2018
• A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis 2017
• Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma 2017
• Daratumumab in Combination with Dexamethasone in Resistant or Refractory Multiple Myeloma: Primary Results of the IFM2014-04 Trial 2016
• Ibrutinib Monotherapy in Relapse or Refractory Primary CNS Lymphoma (PCNSL) and Primary Vitreo-Retinal Lymphoma (PVRL). Result of the Interim Analysis of the iLOC Phase II Study from the Lysa and the French LOC Network 2016
• Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma 2016
• Can Assessment of Patient Monoclonal Immunoglobulins By Heavy/Light Analysis be Used to Assign Patient Responses Analogous to IMWG Response Criteria? 2015
• Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations 2015
• Impact of Anti-CD20 Antibodies on the Incidence of Secondary Cancers in Patients Treated for Chronic Lymphocytic Leukemia 2015
• Impact of Poor Tolerance and Discontinuation of the Dexamethasone during Treatment with Lenalidomide-Dexamethasone in Relapsed and Refractory Multiple Myeloma 2015
• Molecular Subgroups of Hyperdiploidy and Their Prognostic Relevance - an Analysis of 1,036 Myeloma Trial Patients 2015
• Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC 2015
• Spatiotemporal Analysis of Intraclonal Heterogeneity in Multiple Myeloma: Unravelling the Impact of Treatment and the Propagating Capacity of Subclones Using Whole Exome Sequencing 2015
• Specific Identification of High Risk Disease Using Molecular Profiling By Mymap (Myeloma MLPA and translocation PCR) of 1,036 Cases 2015
• Apobec Family Mutational Signatures Are Associated with Poor Prognosis Translocations in Multiple Myeloma 2014
• Characterization of RAS Alterations in Myeloma: Why Direct Targeting of RAS May be the Most Appropriate Therapeutic Approach 2014
• Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques 2014
• Exome Sequencing to Define a Genetic Signature of Plasma Cells in Systemic AL Amyloidosis 2014
• High Resolution Genome Wide DNA Methylation Analysis in a Large Trial Group Reveals a Novel Epigenetically Defined Subgroup of Myeloma Patients Characterized By Developmental Gene Hypermethylation 2014
• High Throughput Genetic Profiling Using a Robust All-Molecular Diagnostic Approach Is Feasible to Specifically Identify a High Risk Group of Myeloma Patients 2014
• Mutational Patterns and Copy Number Changes at Diagnosis Are a Powerful Tool to Predict Outcome: Result of the Sequencing Study of 463 Newly Diagnosed Myeloma Trial Patients 2014
• Rapid, Robust and Accessible Molecular Profiling of Biologically and Clinically Relevant Copy Number Alterations in Multiple Myeloma from Small Amounts of Tumor DNA 2014
• Somatic Mutation Spectrum in Monoclonal Gammopathy of Undetermined Significance Compared to Multiple Myeloma 2014
• The Extent of Intra-Clonal Genetic Diversity within the Myeloma Clone Is a Predictive Biomarker of Progression and Outcome after Treatment 2014
• The Spectrum of Epigenetic Mutations in Myeloma and Their Clinical Impact 2014
• Co-Existent Hyperdiploidy Does Not Abrogate The Poor Prognosis Associated With Adverse Cytogenetics In Myeloma 2013
• Exome Sequencing To Define A Genetic Signature Of Plasma Cells In Systemic AL Amyloidosis 2013
• Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients 2013
• The Value Of Serum Free Light Chain Monitoring Compared To Urinary Bence-Jones Measurement In Light Chain Only Myeloma 2013
• B-Cell-Specific Transcription Factor BACH2 Involved in the Clinical Behavior Heterogeneity of Waldenstrom Macroglobulinemia 2012
• Blocking Vasoactive Intestinal Peptide Signaling Enhances Anti-Viral Immunity without Increased Graft Versus Host Disease in Murine Allogeneic Bone Marrow Transplantation 2011
• Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia 2011
• Risk Factors of Thromboembolic Events in Multiple Myeloma Treated with IMiDs-Based Therapy While on LMWH Prophylaxis 2011
• The EDS® System for the Detection of Bone Lesions in Patients with Multiple Myeloma 2011
• CD11b-donor dendritic cells elevate donor T-Cell production of interferon-gamma and graft-versus-leukemia activity in allogeneic bone marrow transplantation 2007
• The absence of vasoactive intestinal peptide augments allo-reactivity and the anti-viral response in bone marrow transplantation 2007